Axonics
AXNX

$68.49

0.75%

Market Cap: 3.49B

About: Axonics Inc is a United States-based medical technology company. It focuses on developing and commercializing novel products for adults with bladder and bowel dysfunction, that include implantable SNM systems to treat urinary urge incontinence and urinary urgency frequency (UUF); a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence. SNM therapy is predominantly used to treat patients with overactive bladder, fecal incontinence, and urinary retention. Geographically, the company generates majority of its revenue from United States and rest from International markets.

Employees: 797

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,702 funds

–

Analysts bullish %

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

300% more funds holding in top 10

Funds holding in top 10: 4 [Q4 2023] → 16 (+12) [Q1 2024]

1% less funds holding

Funds holding: 226 [Q4 2023] → 224 (-2) [Q1 2024]

3% less first-time investments, than exits

New positions opened: 76 | Existing positions closed: 78

8% less capital invested

Capital invested by funds: $3.16B [Q4 2023] → $2.92B (-$242M) [Q1 2024]

17.05% less ownership

Funds ownership: 100.09% [Q4 2023] → 83.03% (-17.05%) [Q1 2024]

20% less call options, than puts

Call options by funds: $17.3M | Put options by funds: $21.6M

53% less repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 85

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price forecasts over the past 6 months

Low target

$71

4%

upside

Avg. target

$71

4%

upside

High target

$71

4%

upside

1 analyst rating

0 positive

0%

1 neutral

100%

0 negative

0%

RBC Capital

Shagun Singh

4%upside

$71

Sector Perform

Reiterated

29 Feb 2024

See Analyst Rankings

Financial journalist opinion

Axonics Receives Regulatory Approval for Recharge-Free SNM System in Australia

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics F15™ recharge-free sacral neuromodulation (SNM) system in Australia to treat adults with overactive bladder. “Approval of the Axonics recharge-free system is welcome news for Australians with bladder and bowel dysfunction,” said Dr. Ailsa Wilson Edwards, a urologist at Calvary North Adelaide Hospital. “I.

Axonics Receives Regulatory Approval for Recharge-Free SNM System in Australia

Axonics Reports First Quarter 2024 Financial Results

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results for the three months ended March 31, 2024. “Our commercial team continued to execute at a high level in the first quarter, generating revenue growth of 29% year over year across our portfolio of incontinence products,” said Raymond W. Cohen, chief executive.

Axonics Reports First Quarter 2024 Financial Results

Boston Scientific Announces Results for First Quarter 2024

MARLBOROUGH, Mass. , April 24, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.856 billion during the first quarter of 2024, growing 13.8 percent on a reported basis, 15.0 percent on an operational1 basis and 13.1 percent on an organic2 basis, all compared to the prior year period.

Boston Scientific Announces Results for First Quarter 2024

FTC seeks more information on Boston Scientific's $3.7 bln Axonics deal

Boston Scientific said on Thursday the U.S. Federal Trade Commission (FTC) has requested additional information from the medical device maker related to its $3.7 billion deal to buy Axonics.

FTC seeks more information on Boston Scientific's $3.7 bln Axonics deal

Zacks Investment Research

All You Need to Know About Axonics (AXNX) Rating Upgrade to Buy

Axonics (AXNX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Axonics (AXNX) Rating Upgrade to Buy

Axonics Stockholders Approve Merger Agreement with Boston Scientific

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) announced that its stockholders have voted today to adopt Axonics' merger agreement with Boston Scientific Corporation (NYSE: BSX). According to preliminary voting results from the special meeting of stockholders held earlier today, a majority of the shares of Axonics' common stock outstanding and entitled to vote at the special meeting voted in favor of adopting the merger agreement. Final voting results, as tabulated by an independ.

Axonics Stockholders Approve Merger Agreement with Boston Scientific

Axonics Provides Update on Inter Partes Review Proceedings

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued written decisions on two Medtronic patents that Axonics is contesting. The PTAB issued its decision with respect to Patent Nos. 8,626,314 (“the ‘314 patent”) and 8,036,756 (“the ‘756 patent”). Medtronic has asserted these patents, which expired in 2021 and 2022, against Axonics' proprietary tined lead design. Today, the PT.

Axonics Provides Update on Inter Partes Review Proceedings

Zacks Investment Research

Axonics (AXNX) Gets CE Mark for Sacral Neuromodulation System

Axonics' (AXNX) fourth-generation rechargeable Sacral Neuromodulation system will reduce the frequency of patient recharges significantly. The new form factor ensures ease of use.

Axonics (AXNX) Gets CE Mark for Sacral Neuromodulation System

Axonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the Axonics R20™ rechargeable sacral neuromodulation (SNM) system has received CE Mark approval. The R20 neurostimulator is labeled for a functional life in the body of at least 20 years and reduces how frequently a patient needs to recharge their implanted device to once.

Axonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System

Axonics Responds to ITC Action by Medtronic

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received notice that Medtronic has filed a complaint with the U.S. International Trade Commission (ITC), along with a parallel action in U.S. District Court for the District of Delaware. The complaint alleges that Axonics infringes two Medtronic patents that purportedly relate to a “patient programmer with automated MRI compatibility verification” for an implantable medical device. “We believe Medtronic's.

Axonics Responds to ITC Action by Medtronic

See News Rankings